Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

A Phase II Study of Oral Interferon-Alpha (IFN-a) for Patients with Essential Thrombocythemia or Polycythemia Vera.

Alfonso Quintas-Cardama, MD, Francis Giles, M.D., Jorge Cortes, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4880.

https://doi.org/10.1182/blood.V108.11.4880.4880

Published: 2006

Journal Articles

Denileukin Diftitox (Ontak™) Therapy for Patients with Systemic Mastocytosis.

Alfonso Quintas-Cardama, MD, Hagop Kantarjian, M.D., Francis Giles, M.D., Jorge Cortes, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4881.

https://doi.org/10.1182/blood.V108.11.4881.4881

Published: 2006

Journal Articles

The Novel Tyrosine Kinase Inhibitor (TKI) Exel-0862 Potently Induces Apoptosis in Human FIP1L1-PDGFR-α-Expressing Cells through Caspase-Dependent Cleavage of MCL-1.

Jingpan Pan, MD, PhD, Alfonso Quintas-Cardama, M.D., Hagop Kantarjian, M.D., Peter Lamb, Ayalew Tefferi, Jorge Cortes, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4882.

https://doi.org/10.1182/blood.V108.11.4882.4882

Published: 2006

Journal Articles

Treatment with Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; PEGASYS™) for Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV).

Alfonso Quintas-Cardama, MD, Hagop Kantarjian, M.D., Francis Giles, M.D., Jorge Cortes, M.D., Mary Ann Richie, R.N., Gautam Borthakur, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4884.

https://doi.org/10.1182/blood.V108.11.4884.4884

Published: 2006

Journal Articles

WP1066 Inhibits Growth of Human Cells Carrying the JAK2 V617F Mutation.

Taghi Manshouri, PhD, Zeev Estrov, M.D., Alfonso Quintas-Cardama, M.D., Jorge Cortes, M.D., Francis Giles, M.D., David Harris, MS, Waldemar Priebe, PhD;MS, Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD.

Blood (2006) 108 (11): 4885.

https://doi.org/10.1182/blood.V108.11.4885.4885

Published: 2006

Journal Articles

Interferon Therapy Is Predictive Factor for Improved Survival in Patients with Essential Thrombocythemia (ET).

Elias Jabbour, MD, Antoine Harb, M.D., Francis Giles, M.D., Jorge Cortes, M.D., Sherry Pierce, BSN.BA, Jianqin Shan, Zeev Estrov, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4897.

https://doi.org/10.1182/blood.V108.11.4897.4897

Published: 2006

Journal Articles

Alemtuzumab (CAMPATH-1H ™ ) Is Effective Therapy for Hypereosinophilic Syndrome (HES).

Alfonso Quintas-Cardama, MD, Ayalew Tefferi, M.D., Jorge Cortes, M.D., Animesh Pardanani, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Pat Ault, R.N., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4902.

https://doi.org/10.1182/blood.V108.11.4902.4902

Published: 2006

Journal Articles

Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup.

Ehab Atallah, MD, Hagop Kantarjian, M.D., Jorge Cortes, M.D., Sherry Pierce, R.N., Elihu Estey, M.D., Guillermo Garcia-Manero, M.D., Deborah Thomas, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.,; PhD.

Blood (2006) 108 (11): 2612.

https://doi.org/10.1182/blood.V108.11.2612.2612

Published: 2006

Journal Articles

Characteristics and Outcomes of 38 Patients with Acute Myeloid Leukemia Evolving from Previous Well Characterized Myeloproliferative Disorder.

Constantine S. Tam, MD, Francis Giles, M.D., Jorge Cortes, M.D., Guillermo Garcia-Manero, M.D., Elihu Estey, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 2705.

https://doi.org/10.1182/blood.V108.11.2705.2705

Published: 2006

Journal Articles

A Phase II Study of Azacitidine (Vidaza™) for Patients with Myelofibrosis (MF).

Alfonso Quintas-Cardama, MD, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, M.D., Deborah Thomas, M.D., STeven Kornblau, M.D., Elihu Estey, M.D., Marilyn Nemri, R.N., Jorge Cortes, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 2706.

https://doi.org/10.1182/blood.V108.11.2706.2706

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A Phase II Study of Oral Interferon-Alpha (IFN-a) for Patients with Essential Thrombocythemia or Polycythemia Vera.

Denileukin Diftitox (Ontak™) Therapy for Patients with Systemic Mastocytosis.

The Novel Tyrosine Kinase Inhibitor (TKI) Exel-0862 Potently Induces Apoptosis in Human FIP1L1-PDGFR-α-Expressing Cells through Caspase-Dependent Cleavage of MCL-1.

Treatment with Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; PEGASYS™) for Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV).

WP1066 Inhibits Growth of Human Cells Carrying the JAK2 V617F Mutation.

Interferon Therapy Is Predictive Factor for Improved Survival in Patients with Essential Thrombocythemia (ET).

Alemtuzumab (CAMPATH-1H ™ ) Is Effective Therapy for Hypereosinophilic Syndrome (HES).

Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup.

Characteristics and Outcomes of 38 Patients with Acute Myeloid Leukemia Evolving from Previous Well Characterized Myeloproliferative Disorder.

A Phase II Study of Azacitidine (Vidaza™) for Patients with Myelofibrosis (MF).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only